Combination Growth Hormone and IGF-1 Therapy for Childhood Short Stature Terminated
Background
Children suffering from short stature due to Insulin-like Growth Factor-1 (IGF-1) deficiency often receive treatment with recombinant human Growth Hormone (rhGH). While rhGH alone can be effective, some patients show suboptimal responses, suggesting a need for alternative or combined approaches. This study aimed to investigate if adding recombinant human Insulin-like Growth Factor-1 (rhIGF-1) to rhGH therapy could offer superior outcomes for these children.
Study Design
Results
This Phase 2 clinical trial, designed to evaluate combination therapy for IGF-1 deficiency, was TERMINATED prematurely on March 2012, before its scheduled completion. Consequently, no efficacy or safety data regarding the comparative benefits of rhGH alone versus rhGH + rhIGF-1 at various doses were reported. This means the primary objective of determining an optimal dose for combination therapy in 106 children with IGF-1 deficiency could not be fulfilled. > The most significant finding from this record is the trial's premature TERMINATION, leaving the question of optimal combination therapy unanswered. The study's termination prevents any quantitative comparison between the treatment arms, and no specific data on growth velocity or IGF-1 levels were released.
Why It Matters
The termination of this trial highlights the significant challenges in developing and testing combination therapies for complex conditions like IGF-1 deficiency and short stature. While this specific study did not yield results, the underlying hypothesis—that combining rhGH with rhIGF-1 might improve outcomes for non-responders to rhGH monotherapy—remains a critical area of research. Successful development of such a combination could offer a new therapeutic option for children who do not adequately respond to current standard treatments. Future research will need to explore alternative trial designs or patient populations to address this unmet medical need, potentially moving towards new Phase 2 or Phase 3 human trials.